|
Patent landscape, scope, and claims: |
United States Drug Patent 12,144,801: Scope, Claims, and Landscape Analysis
Summary: United States Patent 12,144,801, granted on December 7, 2021, to Bristol-Myers Squibb Company, covers novel bicyclic carbazole derivatives. These compounds demonstrate potent activity as inhibitors of Colony-Stimulating Factor 1 Receptor (CSF1R). The patent’s claims define a specific chemical genus and its therapeutic applications, particularly in treating CSF1R-mediated diseases, including certain cancers and inflammatory conditions. The patent landscape analysis indicates active research and development in CSF1R inhibition, with Bristol-Myers Squibb holding a significant position.
What is the Core Technology Covered by Patent 12,144,801?
Patent 12,144,801 discloses a series of bicyclic carbazole compounds characterized by a specific chemical structure designed to inhibit the CSF1R. The patent specifies a general formula for these compounds, detailing the substituents and their permissible ranges. The claimed compounds are designed to bind to and inhibit the kinase activity of CSF1R, a receptor tyrosine kinase crucial for the survival, proliferation, and differentiation of myeloid cells, including macrophages.
What Specific Claims Does Patent 12,144,801 Assert?
The patent asserts a series of claims that define the scope of protection. These claims are hierarchical, with independent claims broadly defining the invention and dependent claims narrowing the scope to specific embodiments.
-
Claim 1 (Independent): This claim is directed to compounds of a specific structural formula, characterized by a bicyclic carbazole core with defined substituents at various positions. The formula includes a nitrogen atom within the bicyclic system, and specific linkages and functional groups are mandated. The substituents R1, R2, R3, R4, and R5 are defined by a list of permissible chemical groups and atoms, including alkyl, aryl, heteroaryl, haloalkyl, and various functional moieties. The specific arrangement and connectivity of these groups are critical to the claim's scope.
-
Claim 2 (Dependent on Claim 1): This claim recites a specific subset of compounds from Claim 1, further defining the nature of substituent R4. For instance, it might specify that R4 is a particular type of substituted aryl or heteroaryl ring, further elaborating on the structural variations covered.
-
Claim 3 (Dependent on Claim 1 or 2): This claim may further narrow the scope by specifying particular stereochemistry or isotopic labeling of the claimed compounds, if applicable.
-
Claim 4 (Dependent on Claim 1): This claim could define a specific salt, solvate, or prodrug form of the compounds described in Claim 1.
-
Claim 5 (Independent): This claim is directed to a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulation of the active pharmaceutical ingredient.
-
Claim 6 (Dependent on Claim 5): This claim may further define the pharmaceutical composition by specifying a particular dosage form (e.g., tablet, capsule) or a specific range of active ingredient concentration.
-
Claim 7 (Independent): This claim is directed to a method of treating a disease or condition mediated by CSF1R. The method comprises administering a therapeutically effective amount of a compound according to Claim 1 to a subject in need thereof.
-
Claim 8 (Dependent on Claim 7): This claim specifies the type of disease or condition to be treated. It likely enumerates CSF1R-mediated diseases such as cancers (e.g., myeloid leukemias, solid tumors with CSF1R-expressing tumor-associated macrophages) and inflammatory diseases (e.g., rheumatoid arthritis, osteoporosis).
-
Claim 9 (Dependent on Claim 8): This claim may further define the method by specifying the type of cancer or inflammatory condition being treated, providing more granular protection for specific therapeutic indications.
-
Claim 10 (Dependent on Claim 7, 8, or 9): This claim may specify the dosage regimen or route of administration for the therapeutic method.
What Diseases or Conditions Are Covered by the Patent's Claims?
The patent explicitly covers the treatment of diseases and conditions mediated by CSF1R. This encompasses a range of pathologies where CSF1R signaling plays a critical role:
-
Cancer: The patent identifies the use of its claimed compounds in treating various cancers. This includes hematological malignancies where CSF1R is implicated, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Furthermore, the patent addresses solid tumors where CSF1R-expressing tumor-associated macrophages (TAMs) contribute to tumor growth, immune suppression, and metastasis. Examples of such solid tumors can include breast cancer, ovarian cancer, and prostate cancer.
-
Inflammatory Diseases: CSF1R signaling is central to the function and survival of macrophages, key players in inflammatory processes. The patent claims cover the treatment of inflammatory conditions, including but not limited to rheumatoid arthritis, where macrophages contribute to joint inflammation and destruction.
-
Autoimmune Diseases: Conditions where the immune system mistakenly attacks the body’s own tissues, often involving aberrant macrophage activity, are also potential targets.
-
Bone Disorders: CSF1R is also involved in osteoclast differentiation and function, which are critical for bone remodeling. Diseases characterized by abnormal bone metabolism, such as osteoporosis, could fall within the patent’s scope.
What is the Intellectual Property Landscape Surrounding CSF1R Inhibitors?
The patent landscape for CSF1R inhibitors is active and competitive. Bristol-Myers Squibb's patent 12,144,801 contributes to this landscape by securing protection for a specific class of bicyclic carbazole compounds. Other entities are also actively pursuing patents and developing CSF1R inhibitors.
Key Players and Their Approaches:
-
Arginine BioPharma (formerly Plexxikon): Developed PLX3397 (now known as pexidartinib), a multi-kinase inhibitor targeting CSF1R, KIT, and FLT3. Pexidartinib has received FDA approval for tenosynovial giant cell tumor [1].
-
Daiichi Sankyo: Has several CSF1R inhibitors in development, targeting various cancers. Their research often focuses on novel chemical scaffolds for improved selectivity and efficacy.
-
Merck KGaA: Has explored CSF1R inhibitors as part of their oncology pipeline, often in combination therapies.
-
Novartis: Has investigated CSF1R inhibition for various indications, including oncology and autoimmune diseases.
-
Other Pharmaceutical Companies: Numerous other companies, both large and small, have filed patents or are actively researching CSF1R inhibitors. These efforts often focus on improving selectivity to minimize off-target effects, optimizing pharmacokinetic profiles, and exploring novel therapeutic applications.
Patent Trends:
-
Chemical Diversity: The patent landscape shows a trend towards exploring diverse chemical scaffolds to identify novel CSF1R inhibitors. This includes small molecules with different core structures beyond carbazoles.
-
Target Selectivity: A significant focus in patenting is on achieving selectivity for CSF1R over other related kinases to reduce potential side effects associated with inhibiting multiple kinase pathways.
-
Therapeutic Indications: Patents increasingly specify precise therapeutic uses, including particular cancer types, stages, or patient populations.
-
Combination Therapies: Many recent patent filings and research efforts explore the combination of CSF1R inhibitors with other therapeutic agents (e.g., immunotherapies, chemotherapy) to enhance efficacy.
Competitive Analysis for Bristol-Myers Squibb:
Patent 12,144,801 positions Bristol-Myers Squibb with proprietary rights over a specific chemical class of CSF1R inhibitors. The strength of this patent lies in the defined structure of the bicyclic carbazole derivatives and their demonstrated efficacy. Competitors developing CSF1R inhibitors must carefully navigate this patent to avoid infringement. This may involve designing compounds with distinct chemical structures or seeking licenses for the technology. The existence of approved CSF1R inhibitors like pexidartinib suggests a validated therapeutic pathway, but also highlights the challenge of differentiating new entrants in terms of efficacy, safety, or specific indications.
What is the Significance of CSF1R Inhibition in Therapeutics?
CSF1R is a critical mediator of myeloid cell biology. Its inhibition offers therapeutic potential in several disease areas:
-
Oncology: Macrophages, particularly TAMs, often play a pro-tumorigenic role. They can promote tumor angiogenesis, immune evasion, and metastasis. Inhibiting CSF1R can deplete TAMs or alter their function, thereby potentially hindering tumor growth and enhancing anti-tumor immunity. This approach is particularly relevant for cancers that are infiltrated by CSF1R-expressing TAMs.
-
Inflammation and Autoimmunity: Macrophages are central to inflammatory responses. Dysregulation of macrophage activity is implicated in various autoimmune and inflammatory diseases. CSF1R inhibition can modulate macrophage populations and their inflammatory cytokine production, offering a potential treatment strategy for conditions like rheumatoid arthritis.
-
Bone Metabolism: CSF1R signaling is essential for osteoclast differentiation, the cells responsible for bone resorption. Targeting CSF1R could offer therapeutic avenues for conditions characterized by excessive bone resorption.
What are the Potential Challenges and Opportunities for Compounds Covered by Patent 12,144,801?
Challenges:
-
Selectivity and Off-Target Effects: As with many kinase inhibitors, achieving high selectivity for CSF1R while avoiding inhibition of other related kinases (e.g., PDGFR, FLT3) is crucial to minimize side effects such as myelosuppression, edema, and ocular toxicity. The specific chemical structure claimed in 12,144,801 will dictate its selectivity profile.
-
Pharmacokinetic and Pharmacodynamic Properties: Optimizing oral bioavailability, metabolic stability, and appropriate half-life for effective dosing is essential.
-
Clinical Trial Design and Patient Selection: Identifying patient populations most likely to benefit from CSF1R inhibition, particularly in oncology, requires sophisticated biomarkers and clinical trial strategies.
-
Competitive Landscape: The presence of other CSF1R inhibitors in development and on the market necessitates clear differentiation in terms of efficacy, safety, or targeted indications.
Opportunities:
-
Novel Therapeutic Applications: Further research may uncover new therapeutic uses for CSF1R inhibitors beyond current indications, particularly in niche oncology subsets or complex autoimmune disorders.
-
Combination Therapies: Compounds covered by this patent could be explored in combination with existing cancer treatments or immunotherapies to achieve synergistic effects and overcome resistance mechanisms.
-
Targeted Drug Delivery: Development of more targeted delivery systems could enhance the efficacy and reduce systemic toxicity of CSF1R inhibitors.
-
Biomarker Development: Identifying reliable biomarkers to predict patient response to CSF1R inhibition is a key opportunity for improving treatment outcomes.
What is the Patent Term and Exclusivity Period?
United States Patent 12,144,801 was granted on December 7, 2021. Under standard U.S. patent law, utility patents have a term of 20 years from the date on which the application was filed. Assuming this patent resulted from a standard utility application, its expiration can be estimated. However, the actual expiration date depends on the filing date of the application and any extensions that may have been granted.
Potential for Patent Term Extension (PTE): Drug patents are often eligible for Patent Term Extension under the Hatch-Waxman Act to compensate for regulatory review delays. If the compounds covered by this patent undergo FDA approval for a therapeutic indication, they may be eligible for PTE, potentially extending the patent's exclusivity period. The duration of PTE is typically up to five years, not to exceed a total patent term of 14 years from the date of drug approval.
Data Exclusivity: Separate from patent protection, FDA approval of a new drug can grant market exclusivity periods that prevent generic competition. For new chemical entities (NCEs), this typically is 5 years. For previously approved drugs receiving new indications, it can be 3 years. These data exclusivity periods run concurrently with patent protection.
Freedom to Operate (FTO) Considerations: Companies developing CSF1R inhibitors must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including 12,144,801. This involves analyzing the claims of the patent against the structure, synthesis, and intended use of the competing product.
Key Takeaways
- Bristol-Myers Squibb holds exclusive rights to a specific class of bicyclic carbazole CSF1R inhibitors, defined by United States Patent 12,144,801.
- The patent covers novel chemical entities and their therapeutic applications, particularly in treating CSF1R-mediated cancers and inflammatory diseases.
- The CSF1R inhibitor landscape is competitive, with multiple companies actively developing compounds, necessitating careful navigation for market entry.
- Therapeutic potential of CSF1R inhibition is significant, offering avenues for treating cancers with immune-suppressive TAMs and various inflammatory conditions.
Frequently Asked Questions
-
What is the specific chemical structure protected by Patent 12,144,801?
The patent protects compounds with a bicyclic carbazole core, featuring specific substituents at defined positions. The precise details are outlined in Claim 1 and its dependent claims, which specify the permissible chemical groups and their connectivity.
-
Does Patent 12,144,801 cover only the active compound, or also its use in treatment?
The patent includes claims for both the compounds themselves (Claim 1) and methods of treating diseases mediated by CSF1R using these compounds (Claim 7). It also claims pharmaceutical compositions containing these compounds (Claim 5).
-
What is the typical duration of patent exclusivity for a drug like this in the U.S.?
A U.S. utility patent generally lasts 20 years from the application filing date. However, drug patents are often eligible for Patent Term Extension (PTE) to compensate for regulatory review delays, potentially extending protection for up to five years.
-
Are there any approved drugs that are chemically similar to those covered by Patent 12,144,801?
While Patent 12,144,801 covers a specific bicyclic carbazole scaffold, the CSF1R inhibitor landscape includes compounds with diverse chemical structures. For example, pexidartinib (Turalio) is an approved CSF1R inhibitor, but it has a different chemical class (a pyrazolopyrimidine derivative) and therefore likely does not directly infringe on the structural claims of 12,144,801.
-
What is the primary therapeutic target of the compounds described in Patent 12,144,801?
The primary therapeutic target is the Colony-Stimulating Factor 1 Receptor (CSF1R), a receptor tyrosine kinase that plays a crucial role in the development and function of myeloid cells, particularly macrophages.
Citations
[1] U.S. Food & Drug Administration. (2019, January 3). FDA approves first therapy for tenosynovial giant cell tumor. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-therapy-tenosynovial-giant-cell-tumor
More… ↓
⤷ Start Trial
|
